Kohlberg Kravis Roberts & Co (KKR) will buy Pfizer’s Capsugel business for just under $2.4 billion. In addition to its Vcaps hydroxypropyl methyl cellulose (HPMC) capsules for dry powder inhalation products, Capsugel also manufactures the Xcelodose micro-dosing systems, used for filling DPI capsules.
Capsugel’s corporate headquarters will remain in New Jersey, and all personnel working for the business will stay with Capsugel, according to Pfizer. Capsugel’s president Guido Driesen will continue to lead the company.
Henry R. Kravis and George R. Roberts, co-Chairmen and CEOs of KKR, made this statement: “Capsugel has an excellent portfolio and outstanding reputation for providing high-quality, innovative drug-delivery solutions. We look forward to working with Capsugel’s talented employees and investing in this business. We share Capsugel’s enthusiasm for its future potential to grow, develop and continue to deliver an unmatched quality of products.”
Read the Pfizer press release.
